↓ Skip to main content

Dove Medical Press

Pregabalin for the treatment of generalized anxiety disorder: an update

Overview of attention for article published in Neuropsychiatric Disease and Treatment, June 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
3 news outlets
twitter
5 X users
facebook
2 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
76 Dimensions

Readers on

mendeley
210 Mendeley
Title
Pregabalin for the treatment of generalized anxiety disorder: an update
Published in
Neuropsychiatric Disease and Treatment, June 2013
DOI 10.2147/ndt.s36453
Pubmed ID
Authors

David S Baldwin, Khalil Ajel, Vasilios G Masdrakis, Magda Nowak, Rizwan Rafiq

Abstract

A PREVIOUS REVIEW SUMMARIZED WHAT WAS THEN KNOWN ABOUT THE POTENTIAL ROLE OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD): this review provides an update on its pharmacological properties and presumed mechanism of action, the liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar molecular structure to the inhibitory neurotransmitter gamma amino butyric acid (GABA) but its mechanism of action does not appear to be mediated through effects on GABA. Instead, its anxiolytic effects may arise through high-affinity binding to the alpha-2-delta sub-unit of the P/Q type voltage-gated calcium channel in "over-excited" presynaptic neurons, thereby reducing the release of excitatory neurotransmitters such as glutamate. The findings of randomized controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and broad efficacy in reducing the severity of psychological and physical symptoms of anxiety. It also has efficacy as an augmenting agent after non-response to antidepressant treatment in GAD. Continuing vigilance is needed in assessing its potential abuse liability but the tolerability profile of pregabalin may confer some advantages over other pharmacological treatments in the short term for treatment in patients with GAD.

Timeline
X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 210 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 2 <1%
United Kingdom 1 <1%
Unknown 207 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 29 14%
Student > Bachelor 22 10%
Student > Master 20 10%
Student > Doctoral Student 18 9%
Student > Postgraduate 13 6%
Other 42 20%
Unknown 66 31%
Readers by discipline Count As %
Medicine and Dentistry 49 23%
Pharmacology, Toxicology and Pharmaceutical Science 23 11%
Psychology 23 11%
Agricultural and Biological Sciences 16 8%
Neuroscience 7 3%
Other 20 10%
Unknown 72 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2024.
All research outputs
#1,231,716
of 25,584,565 outputs
Outputs from Neuropsychiatric Disease and Treatment
#160
of 3,120 outputs
Outputs of similar age
#9,772
of 206,928 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#3
of 54 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,120 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,928 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.